SOL-GEL TECHN. IS-10 Total Liabilities
SOL-GEL TECHN. IS-10 total liabilities. Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) has total liabilities worth €5.66 Million EUR (≈ $6.62 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4SG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SOL-GEL TECHN. IS-10 (2021–2025)
Total liabilities of SOL-GEL TECHN. IS-10 from 2021 to 2025. This chart illustrates how SOL-GEL TECHN. IS-10's total liabilities have evolved over time, based on quarterly financial data.
SOL-GEL TECHN. IS-10 Competitors by Total Liabilities
The table below lists competitors of SOL-GEL TECHN. IS-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
|
USA | $282.84 Million |
|
Trisul S.A
SA:TRIS3
|
Brazil | R$1.88 Billion |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
USA | $52.42 Million |
|
Scicom MSC Bhd
KLSE:0099
|
Malaysia | RM43.59 Million |
|
Eureka Group Holdings Ltd
AU:EGH
|
Australia | AU$152.71 Million |
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
USA | $637.85 Million |
|
Provident Agro Tbk
JK:PALM
|
Indonesia | Rp4.70 Trillion |
|
Niagen Bioscience, Inc.
NASDAQ:NAGE
|
USA | $24.06 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SOL-GEL TECHN. IS-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4SG total asset value.
Liquidity & Leverage Metrics
SOL-GEL TECHN. IS-10 Total Liabilities Ratios Explained
SOL-GEL TECHN. IS-10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SOL-GEL TECHN. IS-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual total liabilities of SOL-GEL TECHN. IS-10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.11 Million ≈ $8.31 Million |
+1.57% |
| 2024-12-31 | €7.00 Million ≈ $8.18 Million |
+5.31% |
| 2023-12-31 | €6.64 Million ≈ $7.77 Million |
+50.46% |
| 2022-12-31 | €4.42 Million ≈ $5.16 Million |
-67.52% |
| 2021-12-31 | €13.60 Million ≈ $15.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more